Paxlovid is responsible for most severe treatment of the Covid-19, shows the organization. The risk of the target was started with 85 percent as the treatment at the beginning of the target.
The WHO shows that treatment with paxlovid patients enjoys both treatment with other available agents, such as remdesivir from Gilead, molnupiravir from Merck or treatment with married monoclonal anti-inflammatory drugs.
Het middel van Pfizer is better in het vorkomen van ziekenhuisopname, “heeft minder bijwerkingen dan molnupiravir en is makkelijker toe te dan remdesivir en antilichamen”, aldus de WHO in a declaration.